Novo Nordisk A/S (NYSE:NVO) Shares Sold by Opinicus Capital Inc.

Opinicus Capital Inc. decreased its stake in Novo Nordisk A/S (NYSE:NVO) by 11.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,539 shares of the company’s stock after selling 448 shares during the period. Opinicus Capital Inc.’s holdings in Novo Nordisk A/S were worth $304,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Quattro Financial Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $299,000. Platform Technology Partners grew its stake in Novo Nordisk A/S by 38.7% during the 4th quarter. Platform Technology Partners now owns 5,677 shares of the company’s stock worth $488,000 after buying an additional 1,584 shares during the last quarter. Golden State Wealth Management LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $156,000. Live Oak Private Wealth LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $1,341,000. Finally, Global X Japan Co. Ltd. grew its position in shares of Novo Nordisk A/S by 14.3% during the fourth quarter. Global X Japan Co. Ltd. now owns 18,034 shares of the company’s stock worth $1,551,000 after acquiring an additional 2,254 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $86.39 on Friday. The stock has a fifty day moving average price of $91.86 and a 200 day moving average price of $111.83. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. The stock has a market cap of $387.66 billion, a PE ratio of 26.26, a P/E/G ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Analysts Set New Price Targets

NVO has been the subject of a number of recent research reports. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.